Can my insurance make me fail other drugs before covering a CGRP drug?

Often, yes. That requirement is called step therapy, and many plans still apply it to the CGRP class. Insurers still require step therapy for CGRP drugs despite the AHS 2024 position statement recommending CGRPs as first-line treatment. ([source](https://headachevault.com/barriers)) You can appeal, and a documented trial-and-failure record for the drugs the plan required is usually what the appeal turns on.

What is step therapy for migraine treatment?

Step therapy is an insurer rule that requires you to try and fail one or more lower-cost drugs before it will cover a newer or more expensive one. For migraine, that typically means documenting failed trials of older oral preventives, such as topiramate or a beta-blocker, before a CGRP-targeting drug is approved.

Does the American Headache Society say CGRP can be first-line?

Recent AHS guidance has moved toward positioning CGRP-targeting therapies as first-line options for both prevention and acute treatment, rather than requiring patients to fail older, non-specific drugs before accessing them. Insurer coverage rules have been slower to reflect that.

How do I document failed migraine medications for a prior authorization?

Record each drug, the dose, the length of the trial, and the specific symptoms and side effects, including how the postdrome days went, not just the headache. A continuous, dated symptom timeline your neurologist can attach as a PDF is far harder for a reviewer to dismiss than a verbal history.

Step Therapy vs. First-Line CGRP: Why Your Prior-Auth Still Lags the Guidance

Article · 3 min read

Step therapy still makes migraine patients fail cheaper drugs before CGRP.

Headache specialists cleared CGRP drugs as first-line care. Most insurer step-therapy protocols still make you fail older, cheaper drugs first. Here is the gap, and what to document.

The gap you hit at the pharmacy counter

The prescription is for atogepant. The pharmacy tells you the plan wants a prior authorization first, and the prior authorization wants proof you already tried and failed two older preventives, the ones that gave you weight gain or fog or nothing at all. That wall has a name: step therapy. And this week it is back in front of patients, after Blue Cross Blue Shield of Michigan revised its prior authorization and step therapy coverage criteria effective July 1, 2026. ([source](https://www.bcbsm.com/amslibs/content/dam/public/consumer/forms-documents/pharmacy/prior-authorization-and-step-therapy-guidelines.pdf)). The frustrating part is not that the wall exists. It is that the people who wrote the clinical guidance took it down two years ago, and coverage never followed.

The coverage lag

Call it the coverage lag: the distance between what headache medicine now considers appropriate care and what your plan's prior-auth logic still enforces. Guidelines move at the speed of evidence. Formularies move at the speed of renegotiated contracts, and those two clocks sit years apart. You are living in the space between them, and that space gets measured in attacks you sat through waiting for an approval that was clinically justified the whole time.

Why 'just get the prior auth' misses it

The advice you usually hear is procedural. Get your neurologist to submit the prior auth, attach the notes, appeal if denied. That advice is not wrong, but it treats the delay as paperwork friction instead of a design choice. Step therapy is a rule that assumes the cheapest drug should be tried first regardless of whether the evidence supports starting there. For migraine prevention, the evidence stopped supporting that default. The paperwork advice keeps you politely working inside a system that already changed its own mind about where treatment should start.

What the guidance actually says

The American Headache Society's 2024 position statement stated that CGRP-targeting therapies can be considered first-line for prevention and acute treatment, without requiring patients to first fail older, non-specific drugs. Title: 'Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update.' Journal: Headache. 2024;64:333-341. ([source](https://www.neuroamerica.org/wp-content/uploads/2025/01/Headache-2024-Charles-Calcitonin-gene_E2_80_90related-peptide_E2_80_90targeting-therapies-are-a-first_E2_80_90line-option-for-the-prevention.pdf)) The CGRP class is also not one drug, which is part of why coverage logic struggles with it. It spans monoclonal antibodies given by injection or infusion and oral or nasal gepants used for acute or preventive care.

The current CGRP-targeting class: monoclonal antibodies and gepants. Class and route per each drug's FDA labeling.
Drug	Class	Route	Primary use
Erenumab (Aimovig)	CGRP mAb	Injection	Prevention
Galcanezumab (Emgality)	CGRP mAb	Injection	Prevention
Fremanezumab (Ajovy)	CGRP mAb	Injection	Prevention
Eptinezumab (Vyepti)	CGRP mAb	Infusion	Prevention
Atogepant (Qulipta)	Gepant	Oral	Prevention
Rimegepant (Nurtec ODT)	Gepant	Oral	Acute + prevention
Ubrogepant (Ubrelvy)	Gepant	Oral	Acute
Zavegepant (Zavzpret)	Gepant	Nasal	Acute

What the lag looks like in practice

Here is the sequence a lot of people recognize. You and your neurologist agree a gepant fits your pattern: the aura, the overuse risk from too many triptans, the days you cannot keep a tablet down. The plan denies it and points to step therapy. Try topiramate and a beta-blocker first, each for a documented trial period. You lose two to three months to drugs your specialist did not want, log the side effects, then resubmit with that record. The appeal often succeeds. The cost was the stretch of your life you spent proving a point the guideline had already conceded.

Do not stop a prescribed preventive to speed an appeal

A completed, documented trial is usually what an appeal turns on. Stopping a drug early, against your neurologist's plan, can weaken the exact record you need to win. Insurers typically require documented failure of at least two oral preventive medications, with each trial lasting at least two months, before approving coverage for CGRP-targeted therapies.

What to document, and where Postdrome sits

The thing that consistently moves an appeal is a clean record: which drug, what dose, how long, which symptoms, and what happened to the postdrome days as well as the headache itself. Most tracking stops at the attack. Prior-auth reviewers, and your own neurologist, need the fuller timeline, the fog and residual photophobia that hung on after the pain left, because that is often where an older drug's failure actually shows up. Postdrome keeps that continuous symptom record through the attack and the 24 to 72 hours after, and exports it as a PDF your clinician can attach to the submission. It will not fix your insurer's logic. It makes the paperwork harder to wave away.

When you appeal, the record wins it. Postdrome keeps a continuous symptom timeline through the whole attack and the days after, exportable as a PDF your neurologist can attach to a prior-auth. Lifetime price, on-device, yours to take anywhere.

Written for people who already track and still get denied. Every drug named here is the real current CGRP lineup, and the coverage shift is the 2024 American Headache Society first-line position, not a general impression.

Get Postdrome